ライフサイエンスコーパス: athymic mice

1 owth, invasion, and metastatic efficiency in athymic mice.

2 these cells to form pulmonary metastases in athymic mice.

3 transplanting human bioengineered skin onto athymic mice.

4 owth of xenografted tumors and metastasis in athymic mice.

5 human lung carcinoma xenografts implanted in athymic mice.

6 ed of these bacteria even in immunodeficient athymic mice.

7 carcinoma LS174T grown as s.c. xenografts in athymic mice.

8 an prostate tumor, CWR22, was implanted into athymic mice.

9 ehavior of the tumors that they generated in athymic mice.

10 -7-expressing NIH 3T3 cells formed tumors in athymic mice.

11 transferring immune cells from these mice to athymic mice.

12 age-independent manner and to form tumors in athymic mice.

13 between cells grown as primary xenografts in athymic mice.

14 y inhibit xenograft growth of MCF-7 cells in athymic mice.

15 ion in normal and lymphoma xenograft-bearing athymic mice.

16 1alpha (CHO/MIP-1alpha) were inoculated into athymic mice.

17 E3-dependent differences were not evident in athymic mice.

18 er (MCF-7) cells implanted in ovariectomized athymic mice.

19 arcinoma cells followed by xenografting into athymic mice.

20 from two distinct human cancer cell types in athymic mice.

21 to target human Ramos lymphoma xenografts in athymic mice.

22 mM or 0.1 mM vitamin C, and then grafted to athymic mice.

23 d in vivo by analysis of cecal xenografts in athymic mice.

24 EC) were grafted to full-thickness wounds in athymic mice.

25 age-independent growth, and tumorigenesis in athymic mice.

26 roduction in human glioma U251 xenografts in athymic mice.

27 aft model of angiogenesis (Matrigel plug) in athymic mice.

28 mulated MCF-7 tumor growth in ovariectomized athymic mice.

29 factor-164 (VPF/VEGF(164)) into the ears of athymic mice.

30 3T3 cells expressing mGBP-2 formed tumors in athymic mice.

31 ion of LS-174T colon carcinoma xenografts in athymic mice.

32 their ability to migrate to the skeletons of athymic mice.

33 ized, and cells no longer produced tumors in athymic mice.

34 iac injection of the MDA-MB-231 cell line in athymic mice.

35 effect of dvB7Ig/G207 was not manifested in athymic mice.

36 tastatic potential after i.v. injection into athymic mice.

37 ts tumour growth and metastasis formation in athymic mice.

38 growth of p185HER2/neu-expressing tumors in athymic mice.

39 in trials aimed at reducing tumor growth in athymic mice.

40 tumors were implanted subcutaneously in six athymic mice.

41 dent colony formation and tumor formation in athymic mice.

42 enografts and reduction in hnRNP K levels in athymic mice.

43 h of HER2-overexpressing MCF-7 xenografts in athymic mice.

44 6 weeks after implantation subcutaneously in athymic mice.

45 used to treat established ovarian cancers in athymic mice.

46 o porous calcium phosphate ceramic cubes, in athymic mice.

47 al against experimentally induced gliomas in athymic mice.

48 cells, and H1299 human lung cancer tumors in athymic mice.

49 cted, MCF7 human breast cancer xenografts in athymic mice.

50 noculated stable vIL-6-producing clones into athymic mice.

51 cases, regressed established 786-O tumors in athymic mice.

52 epidermoid carcinoma KB/8.5 implanted sc in athymic mice.

53 uman epidermoid carcinoma A431 xenografts in athymic mice.

54 le of streptozotocin-induced diabetic BALB/c athymic mice.

55 ge-independent growth and produce tumours in athymic mice.

56 ologic dermal substrate, and transplanted to athymic mice.

57 growth factor (bFGF)-induced angiogenesis in athymic mice.

58 s are transplanted to the in vivo setting of athymic mice.

59 semination of human tumor cell xenografts in athymic mice.

60 oma (NPC) was evaluated in NPC xenografts in athymic mice.

61 on of the development of ascites in infected athymic mice.

62 sponse elicited by EBV-immortalized cells in athymic mice.

63 ovirus encoding the lacZ gene and grafted to athymic mice.

64 subcutaneous tumor xenografts established in athymic mice.

65 rowth of MCF-7 cell tumors in ovariectomized athymic mice.

66 ccurrence of spontaneous tumor regression in athymic mice.

67 n promote an effective antitumor response in athymic mice.

68 ratumoral inoculation of s.c. CT26 tumors in athymic mice.

69 d orthotopically to full-thickness wounds on athymic mice.

70 ansfectant after subcutaneous injection into athymic mice.

71 suspension and transplanted subrenally into athymic mice.

72 uman breast and ovarian cancer xenografts in athymic mice.

73 gar; and inhibits transforming efficiency in athymic mice.

74 and in vivo using human tumor xenografts in athymic mice.

75 1 in suprabasal cells when transplanted onto athymic mice.

76 kedly extended latency in tumor formation in athymic mice.

77 cell line significantly more tumorigenic in athymic mice.

78 kitt lymphomas established subcutaneously in athymic mice.

79 man dermis to close full-thickness wounds in athymic mice.

80 modified keratinocytes expressing IGF-I onto athymic mice.

81 pression were able to cause hypercalcemia in athymic mice.

82 sion and metastasis of human cancer cells in athymic mice.

83 05-LU), selected for metastatic phenotype in athymic mice.

84 titutes (CSS) in vitro and after grafting to athymic mice.

85 rafts (n = 5) were grafted orthotopically to athymic mice.

86 growth or acquired ability to form tumors in athymic mice.

87 man glioblastoma cells are nontumorigenic in athymic mice.

88 progressively growing subcutaneous tumors in athymic mice.

89 Rgamma, when transplanted into the dorsum of athymic mice.

90 hondrocytes, and implanted subcutaneously in athymic mice.

91 as well as tumor growth when inoculated into athymic mice.

92 tablished HER2-positive BT-474 xenografts in athymic mice.

93 , leading to the formation of large tumor in athymic mice.

94 T-474) following Ang-(1-7) administration to athymic mice.

95 m tumors when implanted into the fat pads of athymic mice.

96 of tumor cells in vitro and in congenitally athymic mice.

97 ast PET images of colon cancer xenografts in athymic mice.

98 (125)I, (111)In, or (64)Cu in tumor-bearing athymic mice.

99 f 54%), compared with that of PC3V tumors in athymic mice.

100 t survival of HeLa cells in soft agar and in athymic mice.

101 more neutrophils and ingested bacilli in the athymic mice.

102 colon adenocarcinoma xenografts implanted in athymic mice.

103 rated tumors when injected subcutaneously in athymic mice.

104 its antitumor effects in xenograft models in athymic mice.

105 stage colon carcinoma, are nontumorigenic in athymic mice.

106 micrometastasis by 4 weeks in >80% of inbred athymic mice.

107 of H-Ras-transformed cells to form tumors in athymic mice.

108 afts of human colon and pancreatic tumors in athymic mice.

109 tion in xenografts when administered p.o. to athymic mice.

110 n reduced levels of serum, or form tumors in athymic mice.

111 antly inhibited RCC 786-O tumor formation in athymic mice.

112 asis when these cells were transplanted into athymic mice.

113 nd growth as soft agar colonies or tumors in athymic mice.

114 mation in soft agar, and xenograft growth in athymic mice.

115 the ability of these cells to form tumors in athymic mice.

116 ucted with human breast cancer xenografts in athymic mice.

117 in culture or 3T3-F442A cells implanted into athymic mice.

118 tion is detected in MHV-infected young nude (athymic) mice.

119 I]-iodoHoechst 33342 in LS174T tumor-bearing athymic mice 4 h postadministration showed a tumor uptak

120 en-independent relapsed tumors (104-Rrel) in athymic mice after castration.

121 Liver colonization was assessed in athymic mice after splenic-portal inoculation or after s

122 otential, liver colonization was assessed in athymic mice after splenic-portal inoculation.

123 nced regression of PSMA-expressing tumors in athymic mice after systemic administration.

124 rejected by syngeneic C57BL/6 mice, but not athymic mice, after this cell line is transduced to expr

125 cells and fetal pancreatic fibroblasts into athymic mice also failed to result in the development of

126 g the growth of breast cancer tumors in CD-1 athymic mice and caused no normal organ toxicity.

127 colony formation, xenograft-tumor growth in athymic mice and invasion.

128 in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice

129 demonstration of tumor growth inhibition in athymic mice and radiosensitization of human squamous ca

130 ell line, DP-153 cells do not form tumors in athymic mice and retain many of the properties of normal

131 Grafts were transplanted onto athymic mice and studied up to 8 wk.

132 ibroblasts were implanted intradermally into athymic mice and tissue formation was analyzed over time

133 neomycin inhibited PC-3 cell tumor growth in athymic mice and was accompanied by a decrease in both c

134 eries of GBMs, as intracranial xenografts in athymic mice, and administering corresponding p53 inhibi

135 tes were grafted on full-thickness wounds in athymic mice, and biopsy samples for microarray analyses

136 ed differentiation, increased growth rate in athymic mice, and restoration of the basic fibroblast gr

137 n vivo, Mz-ChA-1 cells were s.c. injected in athymic mice, and the effects of GABA on tumor size, tum

138 cells were implanted s.c. in ovariectomized athymic mice, and the growth of the estrogen-dependent t

139 The CBS4 cells are poorly tumorigenic in athymic mice, and the wild-type FET6 cells are nontumori

140 e formation of human breast cancer tumors in athymic mice are indistinguishable.

141 s were administered at 5 mg/kg i.p. daily in athymic mice bearing 1483 human SCCHN xenografts alone o

142 ) was administered by tail vein injection to athymic mice bearing disseminated murine myeloid leukemi

143 r paired-label experiments were performed in athymic mice bearing EGFRvIII-positive xenografts to det

144 Groups of athymic mice bearing HBT 3477 xenografts received 4.1- t

145 both the B16 murine model of melanoma and in athymic mice bearing human A375 xenografts.

146 erived fragments F(ab')2 and Fab', using the athymic mice bearing human colon cancer xenografts.

147 Athymic mice bearing human prostate cancer xenografts we

148 ated after once daily p.o. administration to athymic mice bearing human xenografts and resulted in as

149 To identify such biomarkers, athymic mice bearing L2987 human tumor xenografts were t

150 ting properties were evaluated in vivo using athymic mice bearing LS174T human colon carcinoma xenogr

151 In vivo SPECT imaging was performed using athymic mice bearing MDA-MB-468 or HT1080 xenografts and

152 ing studies with (18)F-TFB were performed in athymic mice bearing NIS-expressing C6-glioma subcutaneo

153 In vivo distribution was evaluated in athymic mice bearing paired LS174T human colon carcinoma

154 In vivo distribution was evaluated in athymic mice bearing paired LS174T human colon carcinoma

155 gonists also inhibit tumor growth in vivo in athymic mice bearing Panc-28 cell xenografts.

156 Athymic mice bearing Ramos human Burkitt's lymphoma xeno

157 Athymic mice bearing Ramos lymphoma xenografts received

158 Athymic mice bearing Ramos lymphoma xenografts received

159 Athymic mice bearing s.c. androgen receptor-negative and

160 or activity of CP-654577 was investigated in athymic mice bearing s.c. tumors from Fischer rat embryo

161 K and 64Cu-TETA-SCK-folate were evaluated in athymic mice bearing small-size KB cell xenografts (10-1

162 -NT-AuNP was injected intratumorally in CD-1 athymic mice bearing subcutaneous EGFR-positive MDA-MB-4

163 4-EGF was studied at 48 h after injection in athymic mice bearing subcutaneous MDA-MB-231/H2N tumors.

164 nd normal-tissue uptake were examined in CD1 athymic mice bearing subcutaneous tumor xenografts that

165 s and sensitivity to Topo II-directed drugs, athymic mice bearing SW480 human colon cancer xenografts

166 Treatment of athymic mice bearing TAMH flank tumors with vehicle or P

167 These studies were done in ovariectomized, athymic mice bearing tumors of estrogen receptor-positiv

168 When transplanted to athymic mice, both composite grafts formed a fully diffe

169 activate p53 in colorectal cancers grown in athymic mice by augmenting phosphorylation of p53 at ser

170 to attenuate retinoblastoma tumor growth in athymic mice by increasing apoptosis.

171 cell lines established from tumors formed in athymic mice by MSU-1.1 cells transformed in culture by

172 cell lines established from tumors formed in athymic mice by MSU-1.1-derived cell strains independent

173 Metastatic tumor formation in athymic mice by PDGF stimulation has not been reported p

174 ariants were evaluated in LS174T xenografted athymic mice by small animal positron emission tomograph

175 Diabetes was induced in nude athymic mice by streptozotocin injections.

176 ll lines tested, and in the tumors formed in athymic mice by these cell lines.

177 ted vessel formation in Matrigel implants in athymic mice by utilizing GFP imaging or magnetic resona

178 When inoculated into athymic mice, calreticulin inhibited Burkitt tumor growt

179 Preclinical studies using athymic mice carrying human tumor xenografts also inform

180 tion and absence of organisms in the skin of athymic mice, compared with euthymic ones.

181 e and TAP1-negative cells produced tumors in athymic mice, confirming that TAP-dependent differences

182 fter irradiation and their tumorigenicity in athymic mice, consistent with the notion that loss of p5

183 al analysis of OSCC tumors that developed in athymic mice demonstrated RANKL and NFATc3 expression in

184 Whole mammary gland transplants into athymic mice demonstrates that the observed dysplasias r

185 in HeLa cells reduces tumor angiogenesis in athymic mice despite the elevated expression level of bF

186 3T3-F442A preadipocytes implanted s.c. into athymic mice develop into fat pads that are indistinguis

187 BMP4 in cell culture and implanted s.c. into athymic mice develop into tissue indistinguishable from

188 In contrast, athymic mice did not develop HIT-like antibodies.

189 Athymic mice displayed a similar neutrophil response wit

190 When transplanted s.c. in athymic mice, DP-153 cells expressing dominant-negative

191 etastasis, cancer cells were inoculated into athymic mice, either into femoral bone marrow cavities o

192 When transplanted into athymic mice, ERT-expressing Hs578t cells showed decreas

193 Athymic mice failed to develop an antibody response to M

194 d into diffusion chambers and implanted into athymic mice for 56 days.

195 The inadequacies of athymic mice for research with grafted tumors are well k

196 age independent growth or tumor formation in athymic mice for the cells treated with RA.

197 Interestingly, injection of VR cells into athymic mice formed malignant ascites in 100% of the ani

198 transplantation, thymus-grafted congenitally athymic mice frequently develop multiorgan autoimmunity.

199 s selected for growth as an ascites tumor in athymic mice from parental MDA-MB-435 cells (435P).

200 ing of NVP-AUY922 (50 mg/kg i.p. or i.v.) to athymic mice generated peak tumor levels at least 100-fo

201 When implanted in athymic mice, HYAL1-v1-expressing tumors grew 3- to 4-fo

202 which these soy protein isolates were fed to athymic mice implanted s.c. with estrogen-dependent tumo

203 Tumors in athymic mice implanted s.c. with GH3 cells resulted in w

204 led UA20 and N3M2 scFvs were administered to athymic mice implanted subcutaneously with DU145 cells.

205 and when these cells were injected s.c. into athymic mice implanted with estrogen pellets, the freque

206 In athymic mice implanted with human tumor xenografts, HTI-

207 failed to impact survival in immunodeficient athymic mice, implicating the role of T cells in prolong

208 ir ability to form tumors and metastasize in athymic mice in comparison to mock-transfected cells (MT

209 bone marrow and spleen cell transplants, in athymic mice, in mice treated with 2-chlorodeoxyadenosin

210 mber of human tumor xenografts grown s.c. in athymic mice, including H460 human lung carcinoma, Colo2

211 tant form of sGC (sGCalpha1beta1(Cys105)) in athymic mice increased the survival time by 4-fold over

212 c. xenografts of human glioblastoma (D54) in athymic mice increased to five times their initial volum

213 aluation in an A431 xenograft tumor model in athymic mice indicated that naamidine A exhibited at lea

214 This response to treatment was lost in athymic mice, indicating a requirement for active host T

215 ry gland growth in 28-day-old ovariectomized athymic mice, indicating that genistein acts as an estro

216 an behave as a T-cell-independent antigen in athymic mice; (iv) the rodent core proteins are not sign

217 lation, virus disseminated to lung tissue of athymic mice, leading to progressive MCMV replication in

218 unocompetent C57BL/6 but not immunodeficient athymic mice, leading to specific immune memory against

219 formation in muscular implantation sites of athymic mice mimics endochondral bone formation.

220 When grafted as epithelial sheets onto athymic mice, modified cells formed a stratified epithel

221 P-alb/UL39 transfection, were established in athymic mice (n = 28) and treated with G207.

222 tes were grafted to full-thickness wounds in athymic mice (n = 8 per group), evaluated for surface el

223 soft agar) and in vivo (s.c. implantation in athymic mice NCRNU-M).

224 th in soft agar as well as tumorigenicity in athymic mice) of A549 lung carcinoma cells and that the

225 After intradermal injection into athymic mice, only fibroblasts expressing active TGF-bet

226 of beta-catenin-deficient chondrocytes into athymic mice persisted for a longer period of time and r

227 Athymic mice rendered leukopenic with cyclophosphamide b

228 ent growth in soft agar to tumorigenicity in athymic mice resulted after a cumulative X-ray dose of 3

229 Intracerebral xenografts of SK-N-MC in athymic mice resulted in a median survival of 23 days in

230 pha-expressing human osteosarcoma cells into athymic mice resulted in larger and more frequent lung m

231 enous TGF-beta1 to the floor of the mouth in athymic mice resulted in marked inhibition of primary tu

232 Oral or i.p. administration of SU6668 in athymic mice resulted in significant growth inhibition o

233 ished human breast tumor xenografts grown in athymic mice resulted in significant inhibition of tumor

234 Adoptive transfer of these T cells to athymic mice resulted in T-cell infiltration of the gut,

235 nes that overexpress Tiam1 into the cecum of athymic mice resulted in tumor growth in the spleen, liv

236 glioma-bearing immunocompetent mice, but not athymic mice, resulted in prolonged survival, suggesting

237 In athymic mice, SCC-S2 transfectants showed significantly

238 Indeed, flt3 ligand (flt3L) treatment of athymic mice subjected to T-cell depletion (without DC d

239 Using athymic mice subjected to T-cell depletion, we observed

240 rmal and serum cytokine levels in normal and athymic mice, suggesting that T cells play a negligible

241 ntext of severe T cell immunodeficiency, and athymic mice that are T-cell-immunodeficient can reject

242 nd evaluate their ability to image tumors in athymic mice that express one or both receptors using sm

243 Moreover, athymic mice that lacked GPC1 exhibited decreased tumor

244 in which a survival advantage was shown for athymic mice that were inoculated with antisense-treated

245 Following intravenous administration to athymic mice, the (111)In complex of 1 was found to sele

246 When transplanted to athymic mice, the grafts formed foci of pigmentation at

247 3ip.1 human epithelial ovarian xenografts in athymic mice, the virus induced complete regression of 8

248 When injected into athymic mice, these cell lines with near normal levels o

249 In athymic mice, these clonotypes do not survive, but can b

250 ted subcutaneously into the flanks of BALB/c athymic mice through an 18-gauge needle.

251 re transplanted under the kidney capsules of athymic mice to analyze the long-term effects of c-Myc a

252 amos, Raji, and FL-18 lymphoma xenografts in athymic mice to assess the potential for improving the e

253 ma cells, was first injected into 5-week-old athymic mice to confirm and compare GRP78 expression in

254 ime PCR in human biopsies and in tumors from athymic mice treated with saline, histamine, histidine d

255 Histologically, athymic mice uniformly developed focal interstitial cell

256 Xenograft tumors were developed in athymic mice using MCA207 cells expressing green fluores

257 n a human prostate adenocarcinoma growing in athymic mice, using near infrared (NIR) dyes as model mo

258 When inoculated into athymic mice, vasostatin significantly reduced growth of

259 vivo, regression of 9L s.c. tumor volumes in athymic mice was achieved only by the multimodal treatme

260 rowth of Daoy, SWB77, and D-54 xenografts in athymic mice was arrested after the depletion of mouse p

261 hA-1 cholangiocarcinoma xenografts in balb/c athymic mice was reduced from 10.9 +/- 1.8 mm(3)/d in mi

262 in-4-positive MDA-MB-468 xenograft tumors in athymic mice was significantly higher than in (111)In-GS

263 tion of PEITC to the PC-3 tumor-bearing male athymic mice were accompanied by statistically significa

264 nt MCF-7 xenograft growth in oophorectomized athymic mice were compared.

265 Athymic mice were found to be markedly resistant to all

266 Athymic mice were injected subcutaneously with Y79 cells

267 Athymic mice were inoculated with A375M melanoma cells.

268 At 2, 4, 6, 8, 14, 21, and 28 days, athymic mice were killed and the nodules (epithelial cys

269 Athymic mice were subcutaneously inoculated with approxi

270 Fifteen athymic mice were treated intravenously with saline (n =

271 umors derived from U87 human glioma cells in athymic mice were treated with oncolytic HSVs G207 or G4

272 Athymic mice were used in an in vivo assay to overcome t

273 l mouse tumors and human tumor xenografts in athymic mice were used to examine the effect of anti-Flk

274 ained from the lungs of chronically infected athymic mice, were inoculated into spinner flasks contai

275 arger and more highly vascularized tumors in athymic mice when compared with control, vector-transfec

276 pletely inhibited transforming efficiency in athymic mice when stably expressed in human tumor cells

277 A-deficient cells formed tumors in castrated athymic mice, whereas LNCaP did not.

278 52 cells, as assayed by s.c. tumor growth in athymic mice, whereas silencing Smad3 alone did not indu

279 as detectable in the brains of LCMV-infected athymic mice which did not develop LCM.

280 -infrared) and injected intravenously into 6 athymic mice which were inoculated orthotopically with g

281 same NSCLC cancer implanted in the lungs of athymic mice (which lack T lymphocytes).

282 ere placed subcutaneously into the flanks of athymic mice, which subsequently formed small nodules.

283 -kappaB activity exhibit decreased growth in athymic mice, which was further reduced by IR with downr

284 ion of XM6:antifos inhibited tumor growth in athymic mice with a corresponding inhibition of c-fos, t

285 These cell lines form fibrosarcomas in athymic mice with a very short latency, and the cells fr

286 Treatment of athymic mice with Apo2L shortly after tumor xenograft in

287 etargeted to human colon tumor xenografts in athymic mice with both the chemical and the diabody bisp

288 istered systemically in C57BL/6 mice or nude/athymic mice with established disseminated MC38 liver me

289 rats bearing the rat mammary tumor (RMT) and athymic mice with HT-39 human tumor xenografts.

290 of this 99mTc-labeled dsFv was evaluated in athymic mice with IL-2 alpha-receptor-positive ATAC4 tum

291 Athymic mice with implanted human MV522 tumors were trea

292 ed of these bacteria even in immunodeficient athymic mice with no apparent side effects.

293 ast cancer xenografts overexpressing HER2 in athymic mice with rhuMAb HER2 resulted in a dose-depende

294 Paired-label comparisons in athymic mice with s.c. U87deltaEGFR xenografts demonstra

295 Athymic mice with tumors resulting from injection of A54

296 the growth of erbB2-overexpressing tumors in athymic mice without overt adverse effects.

297 ty and apoptosis against SKOV3 xenografts in athymic mice without significant weight loss or cytotoxi

298 Athymic mice xenografted with human colorectal adenocarc

299 (human nasopharyngeal carcinoma) cells into athymic mice yielded approximately 0.20 g tumors in 15 d